Bristol-Myers Squibb Company(BMY)Earnings, Financials & Key RatiosBristol-Myers Squibb Company (BMY) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the forward P/E of 9.11 suggests potential value, the significant volatility in net income and the elevated debt-to-equity ratio of 2.21 warrant a cautious, wait-and-see approach.
Bristol-Myers Squibb Company (BMY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Bristol-Myers Squibb Company (BMY) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $1.58vs $1.42+11.3% | $11.5Bvs $10.9B+5.1% |
| Q1 2026 | Feb 5, 2026 | $1.26vs $1.23+2.4% | $12.5Bvs $12.3B+1.8% |
| Q4 2025 | Oct 30, 2025 | $1.63vs $1.52+7.2% | $12.2Bvs $11.9B+3.1% |
| Q3 2025 | Jul 31, 2025 | $1.46vs $1.09+33.9% | $12.3Bvs $11.4B+7.2% |
Recent stock market news and headlines for Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb is generating more than enough earnings to cover its dividend right now. However, the company faces a daunting patent cliff.
Bristol Myers Squibb remains a Strong Buy, supported by steady performance and undervaluation despite recent underperformance versus the benchmark. BMY boasts a 4.43% forward dividend yield, over 2.7x the sector median, with 36 years of uninterrupted payments and 18 years of consecutive growth. Recent double-beat earnings and consistent estimate beats since 2024 reinforce positive sentiment and justify a premium valuation.
BMY's growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1'26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2026 guidance. Strategic partnerships with Jiangsu Hengrui, accretive M&As, and strong uptake of Opdivo Qvantig underpin the company's multi-pronged portfolio renewal efforts, despite the near-term IPRD noise. BMY's intermediate-term top/bottom-line growth prospects are likely to underwhelm due to LOE risks from Eliquis/Opdivo, albeit with secure dividend payouts at 39.2% of free cash flow.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers Squibb focuses on specialized medicines in oncology and immunology, and shares sport a low valuation. Johnson & Johnson offers a diversified business model spanning innovative medicines and medical technology.
Key metrics vs top competitors for Bristol-Myers Squibb Company (BMY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $57.97 | $118.36B | 16.80 | -0.22% | 14.63% | 40.43% | 4.26% | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — | |
| $128.86 | $318.26B | 17.70 | 1.18% | 13.62% | 17.91% | — | |
| $254.65 | $449.91B | 107.45 | 8.57% | 5.79% | 67.46% | — | |
| $1235.56 | $1.17T | 53.84 | 44.7% | 34.98% | 101.17% | — | |
| $267.24 | $643.31B | 24.23 | 6.05% | 21.83% | 26.26% | — |
Bristol-Myers Squibb Company (BMY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Bristol-Myers Squibb Company (BMY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 30, 2026·SEC
Feb 5, 2026·SEC
Jan 12, 2026·SEC
Get notified when BMY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bristol-Myers Squibb Company (BMY) stock FAQ — growth, dividends, profitability & financials explained
Bristol-Myers Squibb Company (BMY) reported $48.48B in revenue for fiscal year 2025. This represents a 222% increase from $15.06B in 1996.
Bristol-Myers Squibb Company (BMY) saw revenue decline by 0.2% over the past year.
Yes, Bristol-Myers Squibb Company (BMY) is profitable, generating $7.28B in net income for fiscal year 2025 (14.6% net margin).
Yes, Bristol-Myers Squibb Company (BMY) pays a dividend with a yield of 4.26%. This makes it attractive for income-focused investors.
Bristol-Myers Squibb Company (BMY) has a return on equity (ROE) of 40.4%. This is excellent, indicating efficient use of shareholder capital.
Bristol-Myers Squibb Company (BMY) generated $11.91B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
